Avoid common mistakes on your manuscript.
Correction to: Neurol Ther (2023) 12:1805–1820 https://doi.org/10.1007/s40120-023-00543-z
In this article Russell Rosenberg is deceased; Chad Ruoff has been denoted as the corresponding author with affiliation ‘Division of Pulmonary Medicine, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA, e-mail: Ruoff.Chad@mayo.edu’.
In Table 2 of this Commentary article, for the number of sleep stage shifts, number of arousals, and patient-reported sleep quality, the values for the REST-ON trial were inadvertently taken from a subgroup analysis of participants taking stimulants presented in Table 2 of the source article [1], rather than from the modified intent-to-treat (mITT) population (reported in Figs. 1–3 of the source article). Additionally, a minus symbol was missing from the value reported for the number of awakenings for the placebo group corresponding to the 6 g dose for SXB trial 2 and values were adjusted to remove “0” after a decimal place where unnecessary for this trial. Table 2 in our Commentary article has been corrected (see next page) to provide the values for the mITT population for the 3 parameters from the REST-ON trial and add the omitted minus symbol and align the decimal places for SXB trial 2.
Similarly, in the section “Both Twice-Nightly and Once-Nightly Oxybate Regimens Improve PSG Measures of DNS, With a Similar Magnitude of Effect” of this article, the number of stage shifts was incorrectly given as − 19.6 (the value for the subgroup analysis) instead of − 20.5 (the value for the modified intent-to-treat population). The corrected sentence is as follows: “Following 13 weeks of SXB-ER treatment (titrated to 9 g), total shifts per night from N1/2/3/REM to wake and N2/3/REM to N1 decreased significantly from baseline (LSM, − 20.5); this trial did not report stage shifts broken down by sleep stage as were reported in SXB trials 1 and 2 [20].”
These corrections do not impact the conclusions of this Commentary article.
The original article has been corrected.
Reference
Roth T, Dauvilliers Y, Thorpy MJ, et al. Effect of FT218, a once-nightly sodium oxybate formulation, on disrupted nighttime sleep in patients with narcolepsy: results from the randomized phase III REST-ON trial. CNS Drugs. 2022;36(4):377–87.
Author information
Authors and Affiliations
Corresponding author
Additional information
Russell Rosenberg passed away after the publication of the commentary.
Rogelio Braceras and Wayne Macfadden are former employees of Jazz Pharmaceuticals.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Rosenberg, R., Braceras, R., Macfadden, W. et al. Correction: Implications of Oxybate Dosing Regimen for Sleep, Sleep Architecture, and Disrupted Nighttime Sleep in Patients with Narcolepsy: A Commentary. Neurol Ther 13, 1315–1319 (2024). https://doi.org/10.1007/s40120-024-00606-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40120-024-00606-9